[go: up one dir, main page]

EP1843745A1 - Formes posologiques de principes actifs contenant de l'hydroxystilbene pour traiter les troubles de la menopause - Google Patents

Formes posologiques de principes actifs contenant de l'hydroxystilbene pour traiter les troubles de la menopause

Info

Publication number
EP1843745A1
EP1843745A1 EP06706622A EP06706622A EP1843745A1 EP 1843745 A1 EP1843745 A1 EP 1843745A1 EP 06706622 A EP06706622 A EP 06706622A EP 06706622 A EP06706622 A EP 06706622A EP 1843745 A1 EP1843745 A1 EP 1843745A1
Authority
EP
European Patent Office
Prior art keywords
dosage form
active ingredient
solid dosage
combination
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06706622A
Other languages
German (de)
English (en)
Inventor
Peter Heger
Reinhard Rettenberger
Carl-Friedrich Spaich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1843745A1 publication Critical patent/EP1843745A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708—Rheum (rhubarb)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Definitions

  • Figure 2 shows the estrogenic activity of 17 ⁇ -oestradiol compared to resveratrol, cis- and trans-rhapontigenin, deoxyrhapontigenin, piceatannol and ERr 731 in a recombinant yeast screen, stably expressing ER- ⁇ .
  • concentrations (X-axis) are molar concentrations with the exception of ERr 731 ® concentration, in ug / ml of indicated.
  • etherifiable or esterifiable groups of a molecule may be derivatized.
  • suitable derivatives and their preparation are described, for example, in FR 2 835 185, to which reference is hereby expressly made.
  • the extracted drug plant is selected in particular from plants of the genus Rheum spp, Astragalus spp. Cassia spp or Picea spp.
  • the active substance core is provided with an enteric-free, preferably plasticizer-free, coating.
  • the main ingredients rhaponticin and deoxyrhaponticin are contained in an approximately 97% proportion in the dry extract.
  • Rhapontigenin and deoxyrhapontigenin together make up 1.1% of the extract, while stilbene, which is still unexplored, contains only 0.2%.
  • Another 3 compounds are contained in a 2.5% proportion.
  • the mixture of Avicel® and active ingredient is sieved through a screening machine (sieve diameter 1.2 mm) into a suitable mixing container and, after addition of the indicated tabletting aids (without magnesium stearate), in a suitable mixer (eg Rhönrad mixer type Standard RR M 200, Engelsmann AG / Ludwigshafen) mixed for at least 30 minutes. After adding magnesium stearate, mix again for at least 5 minutes.
  • a suitable mixer eg Rhönrad mixer type Standard RR M 200, Engelsmann AG / Ludwigshafen
  • HEC-1B cells a human endometrial adenocarcinoma cell line, express neither ERa nor ER ⁇ . Thus, they represent a possibility to investigate ligand-dependent effects of substances on the transactivation mechanisms with respect to different receptor subtypes and different estrogen-responsive promoters in a human and endometrial context.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne de nouvelles formes posologiques contenant de l'hydroxystilbène, des procédés pour produire ces formes posologiques, ainsi que leur utilisation pour traiter les troubles de la ménopause chez la femme, l'oligoménorrhée et la dysménorrhée de l'adolescente, l'aménorrhée primaire et secondaire ou l'endométrite.
EP06706622A 2005-02-04 2006-02-03 Formes posologiques de principes actifs contenant de l'hydroxystilbene pour traiter les troubles de la menopause Withdrawn EP1843745A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005005271 2005-02-04
DE102005005268 2005-02-04
PCT/EP2006/000957 WO2006082073A1 (fr) 2005-02-04 2006-02-03 Formes posologiques de principes actifs contenant de l'hydroxystilbene pour traiter les troubles de la menopause

Publications (1)

Publication Number Publication Date
EP1843745A1 true EP1843745A1 (fr) 2007-10-17

Family

ID=36190656

Family Applications (2)

Application Number Title Priority Date Filing Date
EP06706622A Withdrawn EP1843745A1 (fr) 2005-02-04 2006-02-03 Formes posologiques de principes actifs contenant de l'hydroxystilbene pour traiter les troubles de la menopause
EP20060723000 Active EP1845957B1 (fr) 2005-02-04 2006-02-03 Procede pour produire un extrait medicamenteux contenant des hydroxystilbenes

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP20060723000 Active EP1845957B1 (fr) 2005-02-04 2006-02-03 Procede pour produire un extrait medicamenteux contenant des hydroxystilbenes

Country Status (9)

Country Link
US (4) US8168220B2 (fr)
EP (2) EP1843745A1 (fr)
AT (1) ATE492271T1 (fr)
AU (2) AU2006210119B2 (fr)
CA (2) CA2596178C (fr)
DE (1) DE502006008551D1 (fr)
PL (1) PL1845957T3 (fr)
RU (3) RU2007132963A (fr)
WO (2) WO2006082071A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006210119B2 (en) * 2005-02-04 2011-09-22 Peter Heger Dosage forms of active ingredients containing hydroxystilbene for treating menopausal complaints
PL2520183T3 (pl) 2005-02-04 2017-12-29 Peter Heger Zastosowanie połączenia substancji czynnych zawierające hydroksystilben do leczenia depresji i stanów lękowych
EP1972343B1 (fr) * 2007-03-23 2011-01-12 Navalis Nutraceuticals GmbH Médicament comprenant de l'alchémille pour le traitement de l'endométrite, de la vaginite
FR2922768B1 (fr) * 2007-10-25 2010-01-22 Vetoquinol Sa Procede pour masquer l'amertume d'un extrait sec vegetal de rhubarbe
EP2085077A1 (fr) * 2008-01-30 2009-08-05 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Compositions de revêtement pour formules à libération contrôlée
CN102220387B (zh) * 2011-04-12 2013-02-06 安康中科麦迪森天然药业有限公司 一种从新鲜虎杖中提取纯化白藜芦醇和大黄素的方法
CN102659861B (zh) * 2012-04-18 2015-06-17 昆药集团股份有限公司 一种曲札茋苷的纯化方法
CN102702283B (zh) * 2012-05-08 2014-08-13 青海伊纳维康生物科技有限公司 一种快速分离制备高纯度脱氧土大黄苷和土大黄苷的方法
CN102908410A (zh) * 2012-11-20 2013-02-06 青海伊纳维康生物科技有限公司 一种治疗骨质疏松症和更年期综合症的大黄提取物
CN103070849B (zh) * 2013-01-29 2014-06-04 江苏省中国科学院植物研究所 氧化白藜芦醇在制备抗卵巢衰老药物中的应用
CN103181958A (zh) * 2013-03-21 2013-07-03 河北科技师范学院 治疗奶牛子宫内膜炎的中草药灌注液及其制备方法
CN104605160B (zh) * 2015-01-20 2016-08-17 湖南农业大学 一种防治母猪产后子宫内膜炎的组合物及其应用
CN110227106A (zh) * 2019-05-28 2019-09-13 河南利联科技有限公司 一种治疗痛经的中药组合物及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ181274A (en) 1976-06-24 1979-12-11 New Zealand Forest Prod Extraction of phenolic compounds from bark;adhesives;building boards
DE9414066U1 (de) * 1994-08-31 1994-11-03 Röhm GmbH & Co. KG, 64293 Darmstadt Überzugs- und Bindemittel für Arzneiformen sowie damit hergestellte Arzneiform
EP0840770A4 (fr) 1996-05-23 2002-03-20 Ian Alexander Gilmour Procede d'extraction de proanthocyanidines de substances botaniques
US6414037B1 (en) 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
US6197834B1 (en) * 1998-09-01 2001-03-06 Northeastern Ohio Universities College Of Medicine Method of inhibiting formation of infectious herpes virus particles
US6361815B1 (en) 1998-12-21 2002-03-26 Pure World Botanicals, Inc. Products comprising trihydroxystilbenes and derivatives thereof and methods for their manufacture and use
DE60030845T2 (de) * 1999-01-29 2007-05-03 Sunstar Inc., Takatsuki Arzneimittel, lebensmittel und orale zusammensetzungen die stilben-artige verbindungen enthalten
IT1312377B1 (it) * 1999-03-05 2002-04-15 Uni Ci S R L Composizioni a base di acido tiottico, cisteina e/o n-acetil cisteinada utilizzarsi in preparazioni farmaceutiche, dietetiche e cosmetiche
PE20010540A1 (es) * 1999-07-30 2001-05-15 Procter & Gamble Composicion de fitoalexinas estilbenicas util para la profilaxis y tratamiento de sintomas asociados con el resfriado y enfermedades similares a la influenza
AU7596100A (en) * 1999-09-21 2001-04-24 Rutgers, The State University Resveratrol analogs for prevention of disease
EP2060255B1 (fr) * 2001-11-02 2013-06-05 The Regents of the University of California Compositions pour la prévention et le traitement de maladie inflammatoire, maladie auto-immune, et rejet d'implant
FR2835185B1 (fr) * 2002-01-30 2004-04-02 Berkem Sa Extrait de rhubarbe, compositions obtenues a partir dudit extrait, procede d'obtention et utilisations
WO2005067915A1 (fr) 2004-01-07 2005-07-28 Unilever Plc Combinaisons neuroprotectrices et synergiques de flavanoles, d'hydroxystilbenes, de flavanones, de flavones, de flavonoles, de proanthocyanidins et d'anthocyanidines
PL2520183T3 (pl) 2005-02-04 2017-12-29 Peter Heger Zastosowanie połączenia substancji czynnych zawierające hydroksystilben do leczenia depresji i stanów lękowych
AU2006210119B2 (en) 2005-02-04 2011-09-22 Peter Heger Dosage forms of active ingredients containing hydroxystilbene for treating menopausal complaints
EP1845962A1 (fr) 2005-02-04 2007-10-24 Peter Heger Utilisation de principes actifs contenant de l'hydroxystilbene pour la prevention et/ou le traitement de l'osteoporose

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006082073A1 *

Also Published As

Publication number Publication date
DE502006008551D1 (de) 2011-02-03
WO2006082073A1 (fr) 2006-08-10
EP1845957A1 (fr) 2007-10-24
AU2006210117B2 (en) 2011-07-21
US20140099368A1 (en) 2014-04-10
CA2596178C (fr) 2013-10-08
WO2006082071A1 (fr) 2006-08-10
CA2596189A1 (fr) 2006-08-10
ATE492271T1 (de) 2011-01-15
US20120195942A1 (en) 2012-08-02
RU2007132964A (ru) 2009-03-10
US8168220B2 (en) 2012-05-01
AU2006210119B2 (en) 2011-09-22
EP1845957B1 (fr) 2010-12-22
RU2007132963A (ru) 2009-03-10
AU2006210117A1 (en) 2006-08-10
RU2007132962A (ru) 2009-03-10
CA2596178A1 (fr) 2006-08-10
US20080248069A1 (en) 2008-10-09
PL1845957T3 (pl) 2011-07-29
US20090048184A1 (en) 2009-02-19
AU2006210119A1 (en) 2006-08-10
CA2596189C (fr) 2014-12-16
US9125857B2 (en) 2015-09-08

Similar Documents

Publication Publication Date Title
EP1414937B1 (fr) Extraits de houblon, procede destine a leur preparation et leur utilisation
US20140099368A1 (en) Dosage forms of active ingredients containing hydroxystilbene for treating menopausal complaints
EP1294389B1 (fr) Utilisation therapeutique d'extraits de sophora flavescens ou de sophora subprostrata
DE69218764T2 (de) Pharmazeutische zubereitungen fuer die behandlung von hautschaedigungen
DE69535644T2 (de) Extrakt aus chinesischen Kräutern
EP1294388B1 (fr) Extraits d' especes de sophora, leur procede de production et leur utilisation
DE10206390A1 (de) Verwendung von selektiv den Estrogenrezeptor beta modulierenden phytoestrogenhaltigen Extrakten
DE10113328A1 (de) Kräuterzusammensetzung und Verfahren zur Herstellung einer solchen Zusammensetzung für die Behandlung gynäkologischer Störungen
Mitra et al. Uterine tonic activity of U-3107 a herbal preparation in rats
EP2520183B1 (fr) Utilisation d'agents actifs contenant des hydroxystilbènes pour le traitement de la dépression et de l'anxiété
EP1845962A1 (fr) Utilisation de principes actifs contenant de l'hydroxystilbene pour la prevention et/ou le traitement de l'osteoporose
EP1427430A2 (fr) Utilisation d'extraits de l'espece cimicifuga en tant que medicaments organoselectifs pour traiter des maladies de l'appareil genito-urinaire causees par des hormones sexuelles
EP1904075A2 (fr) Extraits de varietes d'epimedium procedes de fabrication et utilisation
EP1022024A2 (fr) Activité anticholestasique de la lutéoline, apigénine et naringénine
DE102005005276A1 (de) Verwendung von Hydroxystilben-haltigen Wirkstoffen zur Chemoprävention der Tumorgenese und/oder zur Inhibition der Tumorprogression bei endokrin-abhängigen und endokrin-unabhängigen Tumoren
Jiwantare et al. Studies on the histological changes in testes and analysis of serum hormonal level of Aloe vera treatd male albino rat, Rattus norvegicus
DE102005005274A1 (de) Verwendung von Hydroxystilben-haltigen Wirkstoffen zur Prävention und Behandlung chronisch-entzündlicher Erkrankungen
EP1874326A2 (fr) Utilisation d'extraits de racines de griffe du diable (harpagophytum procumbens) pour traiter l'endometriose
DE102005005270A1 (de) Verwendung von Hydroxystilben-haltigen Wirkstoffen zur Behandlung leichter bis mittelschwerer Depressionen und Angstzustände

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070808

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20100709

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20131105